ipilimumab,nivolumab
bms
['nivo', 'niche-2', 'ipilimumab', 'nivolumab']
"unprecedented" pathologic responses were seen after a neoadjuvant 4-week course of ipilimumab plus nivolumab was given before surgery to patients with dmmr #coloncancer, say researchers reporting new results from the niche-2 trial. #esmo22
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.